Abstract
Dysregulated recruitment of leukocytes into the intestine is a characteristic feature of IBD. Several families of molecules regulate the influx of these cells into sites of inflammation within the gastrointestinal tract. Pharmacological blockade of interactions between molecules that mediate the formation of stable bonds (integrins) and their endothelial ligands has already shown clinical efficacy. Antibodies that target participant molecules have been approved by the US Federal Drug Administration for use in Crohn’s, multiple sclerosis (MS) (i.e. natalizumab) and psoriasis (i.e. efalizumab). A more recent additional family of drugs, which might also interfere with lymphocyte traffic (i.e. sphingosine-1- phosphate receptor agonists: fingolimod) is in clinical use for MS and just recently entered the clinical trial stage for ulcerative colitis. In the present review we discuss basic aspects of clinically relevant molecules and compile the clinical studies that support the targeting of specific steps of the leukocyte adhesion cascade for therapeutic purposes in IBD.
Keywords: Adhesion molecules, chemokines, Crohn’s disease, integrins, sphingosine1-phosphate, ulcerative colitis.
Current Drug Targets
Title:Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease
Volume: 14 Issue: 12
Author(s): Giorgos Bamias, David J. Clark and Jesús Rivera-Nieves
Affiliation:
Keywords: Adhesion molecules, chemokines, Crohn’s disease, integrins, sphingosine1-phosphate, ulcerative colitis.
Abstract: Dysregulated recruitment of leukocytes into the intestine is a characteristic feature of IBD. Several families of molecules regulate the influx of these cells into sites of inflammation within the gastrointestinal tract. Pharmacological blockade of interactions between molecules that mediate the formation of stable bonds (integrins) and their endothelial ligands has already shown clinical efficacy. Antibodies that target participant molecules have been approved by the US Federal Drug Administration for use in Crohn’s, multiple sclerosis (MS) (i.e. natalizumab) and psoriasis (i.e. efalizumab). A more recent additional family of drugs, which might also interfere with lymphocyte traffic (i.e. sphingosine-1- phosphate receptor agonists: fingolimod) is in clinical use for MS and just recently entered the clinical trial stage for ulcerative colitis. In the present review we discuss basic aspects of clinically relevant molecules and compile the clinical studies that support the targeting of specific steps of the leukocyte adhesion cascade for therapeutic purposes in IBD.
Export Options
About this article
Cite this article as:
Bamias Giorgos, Clark J. David and Rivera-Nieves Jesús, Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113149990158
DOI https://dx.doi.org/10.2174/13894501113149990158 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Crystallization and Preliminary Crystallographic Analysis of Allograft Inflammatory Factor 1
Protein & Peptide Letters The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease
Current Topics in Medicinal Chemistry Cytokine Network in Inflammatory Bowel Disease
Current Drug Targets - Inflammation & Allergy The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Down with the Erythropoietin. Long Live the Erythropoietin !
Current Drug Targets Neurotrophic Actions of Mood-Stabilizers: A Recent Research Discovery and its Potential Clinical Applications
Current Psychiatry Reviews Neuro-AIDS: Current Status and Challenges to Antiretroviral Drug Therapy (ART) for Its Treatment
Current Drug Therapy Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Targeting Cytokines, Chemokines and Adhesion Molecules in Rheumatoid Arthritis
Current Rheumatology Reviews Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging The Role of the Cytoskeleton in the Life Cycle of Viruses and Intracellular Bacteria: Tracks, Motors, and Polymerization Machines
Current Drug Targets - Infectious Disorders Disease Modifying Therapeutic Strategies in Alzheimers Disease Targeting the Amyloid Cascade
Current Neuropharmacology Echinocandins for the Nursery: An Update
Current Drug Metabolism Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Prediction of Potential Targets of an Emerging Zoonotic Paramyxovirus: An Integrated Bioinformatics Analysis
Current Pharmacogenomics and Personalized Medicine Anti-NMDA Receptor Encephalitis: Efficacy of Treatment for Male Patients and miRNA Biomarker
Current Medicinal Chemistry New Drug Targets for Hepatitis C and Other Flaviviridae Viruses
Infectious Disorders - Drug Targets Evaluation of the Effects of <i>Rumex obtusifolius</i> Seed and Leaf Extracts Against <i>Acanthamoeba</i>: An in vitro Study
Infectious Disorders - Drug Targets New Opportunities in the Structure-based Design of Anti-Protozoan Agents
Current Topics in Medicinal Chemistry Aptamers: Selection, Modification and Application to Nervous System Diseases
Current Medicinal Chemistry